Oncolytics Biotech Inc.

(: ONC.TO)

By |

Equities News

Company chart and information is provided by TradingView based on 15-minute-delayed data.


Profile

Oncolytics Biotech Inc. is developing an intravenously delivered immuno-oncolytic virus called pelareorep, for the treatment of solid tumors and hematological malignancies. Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus that: 1) induces selective tumor lysis, and 2) promotes an inflamed tumor phenotype through innate and adaptive immune responses. Our clinical development plan is based on these two components of the mechanism of action, with a focus on obtaining regulatory approval as soon as possible.

Contact Information

Website: www.oncolyticsbiotech.com
Email: mmoore@oncolytics.ca
Main Phone: +1 403 670-7377
Address: 1167 Kensington Crescent North West
Address 2: Suite 210
State: AB
City / Town: Calgary
Country: CA
Postal Code: T2N 1X7

Issuer Information

Exchange: TSX
CEO: Matthew C. Coffey
Employees: 22
NAICS: Pharmaceutical Preparation Manufacturing(325412)

Equities News

(%)
Company data no longer available
Last Price N/A Change $ N/A Change % N/A Tick N/A
Bid N/A Bid Size N/A Ask N/A Ask Size N/A
Open N/A High N/A Low N/A Prev Close N/A
Last Trade Volume N/A 52 Wk Hi N/A 52 Wk Low N/A
Market Cap N/A Ex-Div Date N/A Div Rate N/A Yield N/A
Shares N/A EPS (TTM) N/A PE Ratio N/A Exchange N/A